Medtronic Management
Management Kriterienprüfungen 2/4
Medtronic CEO ist Geoff Martha , ernannt in Apr 2020, hat eine Amtszeit von 4.58 Jahren. Die jährliche Gesamtvergütung beträgt $20.08M , bestehend aus 6.7% Gehalt und 93.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.006% der Aktien des Unternehmens, im Wert von $6.49M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.6 Jahre bzw. 7.8 Jahre.
Wichtige Informationen
Geoff Martha
Geschäftsführender
US$20.1m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 6.7% |
| Amtszeit als Geschäftsführer | 4.6yrs |
| Eigentum des Geschäftsführers | 0.006% |
| Durchschnittliche Amtszeit des Managements | 3.6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 7.8yrs |
Jüngste Management Updates
Recent updates
Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing
Nov 19Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns
Nov 08
Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)
Oct 31Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?
Oct 13Medtronic: Undervalued Dividend Aristocrat With High Margins
Oct 10An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued
Sep 30Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks
Sep 16Medtronic: An Undervalued Stock With Durable Competitive Advantages
Sep 16Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Sep 05Medtronic: Is The Company Back?
Aug 26Medtronic: Still A Buy Before Earnings
Aug 17Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down
Aug 08Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential
Jul 16At US$77.06, Is Medtronic plc (NYSE:MDT) Worth Looking At Closely?
Jul 11Medtronic (NYSE:MDT) Is Paying Out A Larger Dividend Than Last Year
Jun 27Medtronic: Why I Disagree With The Crowd
Jun 14Medtronic's (NYSE:MDT) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
May 27Medtronic (NYSE:MDT) Has Announced That It Will Be Increasing Its Dividend To $0.70
May 26These 4 Measures Indicate That Medtronic (NYSE:MDT) Is Using Debt Reasonably Well
May 22Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release
May 13Is Medtronic plc (NYSE:MDT) Trading At A 20% Discount?
May 0135% Undervalued? Medtronic's Future Looks Very Bright
Apr 12Medtronic: Buy This Dividend Aristocrat Diamond In The Rough Now
Mar 27Medtronic: Undervalued Medical Devices Stock With Robust Demand And Strong Dividend Growth
Mar 11Medtronic (NYSE:MDT) Has Announced A Dividend Of $0.69
Mar 11Medtronic: Its Recent Beat Proves That It Continues To Be A Rock
Feb 25Results: Medtronic plc Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 22Medtronic: A Good Choice For Dividend Investors Seeking For Low Volatility
Feb 16A Look At The Fair Value Of Medtronic plc (NYSE:MDT)
Jan 31Does Medtronic (NYSE:MDT) Have A Healthy Balance Sheet?
Jan 16Medtronic Stock's Rally Is Set To Continue
Jan 11Medtronic plc's (NYSE:MDT) Price Is Out Of Tune With Earnings
Dec 29Medtronic's (NYSE:MDT) Dividend Will Be $0.69
Dec 12Medtronic: The GLP-1 Drug Headwinds Are Overblown
Dec 103.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic
Nov 28Returns On Capital At Medtronic (NYSE:MDT) Have Hit The Brakes
Nov 19Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings
Nov 17Medtronic Faces Potential Decline Despite Financial Strength
Oct 29An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 21% Undervalued
Oct 19Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly
Oct 04Medtronic: Improved Guidance, Historically Cheap P/E, Yield Reaches 3.5%
Sep 27Medtronic (NYSE:MDT) Is Paying Out A Dividend Of $0.69
Sep 18Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Oct 25 2024 | n/a | n/a | US$4b |
| Jul 26 2024 | n/a | n/a | US$4b |
| Apr 26 2024 | US$20m | US$1m | US$4b |
| Jan 26 2024 | n/a | n/a | US$4b |
| Oct 27 2023 | n/a | n/a | US$4b |
| Jul 28 2023 | n/a | n/a | US$4b |
| Apr 28 2023 | US$15m | US$1m | US$4b |
| Jan 27 2023 | n/a | n/a | US$4b |
| Oct 28 2022 | n/a | n/a | US$4b |
| Jul 29 2022 | n/a | n/a | US$5b |
| Apr 29 2022 | n/a | n/a | US$5b |
| Jan 28 2022 | n/a | n/a | US$5b |
| Oct 29 2021 | n/a | n/a | US$5b |
| Jul 30 2021 | n/a | n/a | US$4b |
| Apr 30 2021 | US$18m | US$1m | US$4b |
| Jan 29 2021 | n/a | n/a | US$3b |
| Oct 30 2020 | n/a | n/a | US$4b |
| Jul 31 2020 | n/a | n/a | US$4b |
| Apr 24 2020 | US$6m | US$905k | US$5b |
| Jan 24 2020 | n/a | n/a | US$5b |
| Oct 25 2019 | n/a | n/a | US$5b |
| Jul 26 2019 | n/a | n/a | US$4b |
| Apr 26 2019 | US$4m | US$693k | US$5b |
Vergütung im Vergleich zum Markt: GeoffDie Gesamtvergütung ($USD20.08M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD12.73M).
Entschädigung vs. Einkommen: GeoffDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
Geoff Martha (54 yo)
4.6yrs
Amtszeit
US$20,084,630
Vergütung
Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Director of NextEra...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.6yrs | US$20.08m | 0.0060% $ 6.5m | |
| Executive VP & President of Cardiovascular Portfolio | no data | US$6.55m | 0.0021% $ 2.3m | |
| Executive VP & President of Neuroscience Portfolio | 5yrs | US$6.44m | 0.00092% $ 992.4k | |
| Executive Vice President of Global Operations & Supply Chain | 3.6yrs | US$7.66m | 0.0015% $ 1.6m | |
| Senior Vice President of Global Financial Planning and Analysis & Interim CFO | less than a year | keine Daten | 0.00045% $ 485.4k | |
| Senior Vice President of Global Operations and Business Services | 8.1yrs | keine Daten | keine Daten | |
| Senior VP | 3.4yrs | keine Daten | 0.0022% $ 2.4m | |
| Senior VP and Chief Technology & Innovation Officer | 1.4yrs | keine Daten | keine Daten | |
| Senior VP and Chief Scientific & Medical Officer | 2.6yrs | keine Daten | keine Daten | |
| VP & Head of Investor Relations | 9.4yrs | keine Daten | keine Daten | |
| Executive VP | 2.8yrs | US$11.72m | 0.0019% $ 2.0m | |
| Senior VP & Chief Communications Officer | 3.8yrs | keine Daten | keine Daten |
3.6yrs
Durchschnittliche Betriebszugehörigkeit
59yo
Durchschnittliches Alter
Erfahrenes Management: MDTDas Führungsteam des Unternehmens gilt als erfahren (3.6 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman of the Board & CEO | 5yrs | US$20.08m | 0.0060% $ 6.5m | |
| Independent Director | 11.8yrs | US$365.06k | 0.0012% $ 1.3m | |
| Independent Director | 17.8yrs | US$350.06k | 0.0015% $ 1.6m | |
| Independent Director | 9.8yrs | US$385.06k | 0.0034% $ 3.6m | |
| Lead Independent Director | 9.8yrs | US$410.06k | 0.0028% $ 3.0m | |
| Independent Director | 5.7yrs | US$370.06k | 0.00048% $ 517.8k | |
| Independent Director | 10.8yrs | US$370.06k | 0.0010% $ 1.1m | |
| Independent Director | 2.4yrs | US$350.06k | 0.00012% $ 129.4k | |
| Independent Director | 4.2yrs | US$370.06k | 0.00032% $ 345.2k | |
| Independent Director | 1.4yrs | US$306.97k | 0% $ 0 |
7.8yrs
Durchschnittliche Betriebszugehörigkeit
63yo
Durchschnittliches Alter
Erfahrener Vorstand: MDTDie Vorstandsmitglieder gelten als erfahren (7.8 Jahre durchschnittliche Amtszeit).